<DOC>
	<DOCNO>NCT00000704</DOCNO>
	<brief_summary>To evaluate long-term safety effectiveness drug 2',3'-dideoxycytidine ( zalcitabine ; ddC ) treat patient AIDS advance AIDS relate complex ( ARC ) . Recent study show certain group drug ( dideoxynucleosides ) effective treat patient HIV infection . ddC dideoxynucleoside test tube study show may valuable treat AIDS patient . ddC show well tolerated certain patient AIDS .</brief_summary>
	<brief_title>A Multicenter Dose Ranging Clinical Trial 2',3'-Dideoxycytidine Treatment Patients With AIDS Advanced ARC .</brief_title>
	<detailed_description>Recent study show certain group drug ( dideoxynucleosides ) effective treat patient HIV infection . ddC dideoxynucleoside test tube study show may valuable treat AIDS patient . ddC show well tolerated certain patient AIDS . A range dose ddC give patient AIDS ARC . Eight patient AIDS eight patient ARC give ddC low level 12 week . Patients respond rise number T4 cell fall HIV antigen serum ( fluid portion blood ) continue dose additional 12 week . Patients respond give dose level ( rise T4 fall serum HIV antigen ) stop treatment 12 week . All patient follow therapy 4 week . As dose level find well tolerated 10 week five eight patient group , additional patient enter high dose level eight AIDS eight ARC patient receive drug give level .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aspirin , acetaminophen , nonsteroidal antiinflammatory agent . Acute therapy ( 7 day ) oral acyclovir . Acute therapy ketoconazole . Exclusion Criteria Coexisting Condition : Patients follow excluded : Negative antigen test within 2 week start therapy . Significant malabsorption ( &gt; 10 percent weight loss within past 3 month serum carotene &lt; 75 IU/ml vitamin A &lt; 75 IU/ml ) . Significant cardiac , liver , neurologic disease . For group A : Opportunistic infection malignancy fulfil definition AIDS , concurrent neoplasm basal cell carcinoma skin situ carcinoma cervix . For group B : Active opportunistic infection , symptomatic visceral Kaposi 's sarcoma ( KS ) , progression KS within month prior study entry , concurrent neoplasm KS , basal cell carcinoma skin , situ carcinoma cervix . Concurrent Medication : Excluded : Acyclovir therapy . Chemoprophylaxis Pneumocystis carinii pneumonia . Other antiretroviral agent , biologic modifier , systemic corticosteroid . Other experimental medication , sedative , barbiturate . Group B : Therapy and/or prophylaxis AIDSdefining opportunistic infection , antineoplastic therapy . Concurrent Treatment : Excluded : Transfusion dependency ( require 2 unit blood per month ) . Patients history idiopathic thrombocytopenia purpura exclude . Prior Medication : Excluded within 30 day study entry : Biologic modifier corticosteroid . Excluded within 90 day study entry : Antiretroviral agent . Prior Treatment : Excluded within 2 week study entry : Transfusion . Inclusion criterion : Consistently positive HIV antigen define Abbott HIV antigen test . This demonstration see two occasion , separate least 72 hour , last must within 2 week start therapy . HIV antigen titer must = &gt; 100 pg . Positive antibody HIV confirm federally license enzymelinked immunosorbent assay ( ELISA ) test kit . The following condition allow : Basal cell carcinoma skin situ carcinoma cervix . Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>HIV Antigens</keyword>
	<keyword>Immunologic Surveillance</keyword>
	<keyword>Zalcitabine</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>CD4-Positive T-Lymphocytes</keyword>
</DOC>